NDAORALTABLET, EXTENDED RELEASE
Approved
Oct 2024
Lifecycle
Growth
Competitive Pressure
0/100
Data completeness
3/8 — Basic
PYRIDOSTIGMINE BROMIDE (pyridostigmine bromide) by Novartis is clinical pharmacology regonol (pyridostigmine bromide injection, usp) an analogue of neostigmine, facilitates the transmission of impulses across the myoneural junction by inhibiting the destruction of acetylcholine by cholinesterase. First approved in 2024.
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Pyridostigmine bromide is an anticholinesterase agent that facilitates neuromuscular transmission by inhibiting acetylcholinesterase, preventing breakdown of acetylcholine at the myoneural junction. The extended-release oral tablet formulation (approved October 2024) offers longer duration of action and fewer adverse effects than neostigmine. It is indicated for reversing neuromuscular blockade from nondepolarizing muscle relaxants and treating myasthenia gravis and related neuromuscular disorders.
Growth12.1 years to LOE
Recent 2024 approval positions this as an emerging growth product with potential for market share capture in perioperative and neuromuscular disorder segments.
Mechanism of Action
CLINICAL PHARMACOLOGY REGONOL (pyridostigmine bromide injection, USP) an analogue of neostigmine, facilitates the transmission of impulses across the myoneural junction by inhibiting the destruction of acetylcholine by cholinesterase. Currently available data indicate that pyridostigmine may have a…
Worked on PYRIDOSTIGMINE BROMIDE at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.